ArticleBMC complementary medicine and therapies2021
Bio-guided isolation of anti-leishmanial natural products from Diospyros gracilescens L. (Ebenaceae).
Article in BMC complementary medicine and therapies, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Probing 5-Nitroimidazole-Triazole Hybrids as Potential Anti-Kinetoplastid Agents: Synthesis and In Vitro Efficacy.ChemMedChem · 2026Article
- In Vitro Leishmanicidal Efficacy of Synthesized Arylidene Analogues of Glitazone.Drug development research · 2025Article
- Synthesis and in vitro antitrypanosomatid activity of novel 5-nitroindole-rhodanine conjugates.Future medicinal chemistry · 2025Article
- Synthesis and In Vitro Antileishmanial Efficacy of Novel Ethylene Glycol Analogues of Benzothiadiazine-1,1-dioxide.Chemistry & biodiversity · 2025Article
- New lignan glycosides fromHeliyon · 2023Article
- Design, synthesis, electrochemistry and anti-trypanosomatid hit/lead identification of nitrofuranylazines.RSC medicinal chemistry · 2023Article
- The GenusPlants (Basel, Switzerland) · 2023Review
- Article
- Exploring novel nitrofuranyl sulfonohydrazides as anti-Leishmania and anti-cancer agents: Synthesis, in vitro efficacy and hit identification.Chemical biology & drug design · 2022Article
- Synthesis, in vitro Antileishmanial Efficacy and Hit/Lead Identification of Nitrofurantoin-Triazole Hybrids.ChemMedChem · 2022Article
- Challenges and Tools for In VitroPathogens (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundPlants represent an intricate and innovative source for the discovery of novel therapeutic remedies for the management of infectious diseases. The current study aimed at discovering new inhibitors of Leishmania spp., using anti-leishmanial activity-guided investigation approach of extracts from Diospyros gracilescens Gürke (1911) (Ebenaceae), targeting the extracellular (promastigotes) and intracellular (amastigotes) forms of Leishmania donovani.
methodsThe plant extracts were prepared by maceration using H
resultsThe hydroethanolic crude extract of D. gracilescens trunk showed the most potent antileishmanial activity (IC
conclusionsThe results obtained indicated that the hydroethanolic extract from the D. gracilescens trunk and the derived hexane fraction have very potent inhibitory effect on cultivated promastigotes and amastigotes of L. donovani parasite. The isolated compounds showed a lesser extent of potency and selectivity. However, further structure-activity-relationship studies of 1-deoxyinositol could lead to more potent and selective hit derivatives of interest for detailed drug discovery program against visceral leishmaniasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.